Affimed`s unique and fully patented TandAb® antibody platform is generating superior antibody therapeutics.
Affimed´s lead program AFM13 enjoys early recognition and protection due to its designation as an Orphan Drug.
RECRUIT-TandAbs® specifically kill various tumor types by recruiting NK- or T-cells.
Affimed is building a mature pipeline of unique therapeutic antibodies for partnership following preclinical or clinical proof of concept studies.
Affimed is a therapeutic antibody company developing unique antibody formats for the treatment of cancer, such as hematological and solid tumors as well as for inflammatory diseases based on its proprietary TandAb® technology platform.
TandAbs® are tetravalent bispecific antibody formats that have two binding sites for each antigen. They bind to target molecules on the surface of, for example,tumor cells and can activate immune effector cells like cytotoxic T-cells or natural killer (NK) cells.
|Compound||Target||Indication||Discovery||Preclinical||Phase I||Phase II|
|blue = current development status - green = planned development|
|AFM13||CD30xCD16A||Hodgkin Lymphoma||100% completed||100% completed||100% completed||30 % 100 %|
|AFM11||CD19xCD3||Non-Hodgkin Lymphoma||100% completed||100 % 100%||100%|